{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:02:39Z","timestamp":1772118159089,"version":"3.50.1"},"reference-count":21,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":4506,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Severe mania is life-threatening, carries an increased risk of suicide and has a serious impact on patients and their families. Efficient and rapid control of episodes of acute mania is needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the safety and efficacy of risperidone monotherapy for acute mania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In a 3-week, randomised, double-blind trial, 290 in-patients with bipolar l disorder with current manic or mixed episode and a baseline Young Mania Rating Scale (YMRS) score of 20 or more received flexible doses of risperidone (1\u20136 mg per day) or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Risperidone was received by 146 patients and placebo by 144. Their mean baselineYMRS score was 37. 2 (s. e. =0. 5). Significantly greater improvements were observed with risperidone than with placebo at weeks l and 2 and at end-point (total YMRS:<jats:italic>P<\/jats:italic>&lt;0. 01). Extrapyramidal symptoms were the most frequently reported adverse events in the risperidone group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with severe manic symptoms, risperidone produced significant improvements in YMRS scores as early as week 1 and substantial changes at end-point. Treatment was well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.187.3.229","type":"journal-article","created":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:09:12Z","timestamp":1125533352000},"page":"229-234","source":"Crossref","is-referenced-by-count":156,"title":["Risperidone in the treatment of acute mania"],"prefix":"10.1192","volume":"187","author":[{"given":"Sumant","family":"Khanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00eblle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000167601_ref13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/ajp.156.8.1164","article-title":"Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-refractory illness and a history of mania","volume":"156","author":"Suppes","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000167601_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770060086012"},{"key":"S0007125000167601_ref7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"S0007125000167601_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"S0007125000167601_ref5","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM)","author":"Guy","year":"1976"},{"key":"S0007125000167601_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"S0007125000167601_ref8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1210"},{"key":"S0007125000167601_ref17","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"},{"key":"S0007125000167601_ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"key":"S0007125000167601_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S0007125000167601_ref14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000167601_ref4","doi-asserted-by":"publisher","DOI":"10.1177\/070674379704200211"},{"key":"S0007125000167601_ref19","unstructured":"World Medical Association (1989) World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. http:\/\/wwwfda.gov\/oc\/health\/hesinki89.htm."},{"key":"S0007125000167601_ref10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"S0007125000167601_ref2","first-page":"233","article-title":"Extrapyramidal Symptom Rating Scale (abstract)","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"S0007125000167601_ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"S0007125000167601_ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S0007125000167601_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hup.556"},{"key":"S0007125000167601_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S0007125000167601_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S0007125000167601_ref12","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial","volume":"21","author":"Segal","year":"1998","journal-title":"Clinical Neuropharmacology"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000167601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:52:38Z","timestamp":1683193958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000167601\/type\/journal_article"}},"subtitle":["Double-blind, placebo-controlled study"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0007125000167601"],"URL":"https:\/\/doi.org\/10.1192\/bjp.187.3.229","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}